Worldwide, breast cancer is one of the most common malignancies, and is the leading cause of cancer-related deaths in women. The most prevalent subtype is HR+/HER2- disease, accounting for approximately 70% of all cases, with 90% of these patients diagnosed in the early stages when there the is the potential for cure. Despite this, approximately 1 in 6 patients diagnosed with HR+ HER2- early breast cancer will experience disease recurrence within 5 years of treatment.
This risk of recurrence is individualized for each patient, and calculated based on factors including nodal involvement, tumor size, and tumor biology, with a variety of approved and emerging treatment options available dependent on these variables.
This expert-led program aims to improve the individualized management of HR+/HER2- early breast cancer through education on recurrence risk classification, current evidence-based guidelines, and new and emerging therapies.
There will also be guidance on integrating shared decision making into your practice drawing on insights from a patient on how best to communicate.
This will be done through news coverage on new data, expert-to-expert video discussions, patient case studies, and the provision of a patient communication guide.
Learning Objectives
Following completion of this independent educational program, you will be able to:
- Classify the risk of recurrence in patients with HR+/HER2- early breast cancer based on key prognostic variables
- Debate the appropriate treatment, both current and emerging, for HR+/HER2- early breast cancer based on recurrence risk
- Integrate tools and guidance on shared decision making to ensure patient preference is a high priority when choosing the management strategy
Target Audience
This independent educational program is suitable for oncologists, oncology nurses, primary care practitioners and those in the multidisciplinary team worldwide who provide front-line care for patients with breast cancer.
Target Audience
This independent educational program is suitable for oncologists, oncology nurses, primary care practitioners and those in the multidisciplinary team worldwide who provide front-line care for patients with breast cancer.
Accreditation
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.
NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates AMA PRA Category 1 Credit™ for the following activities:
Completion of 20-minute video module: 0.25 AMA PRA Category 1 Credit™ (Expiration date: 20th July 2023)
Completion of 15-minute patient case study 1: 0.25 AMA PRA Category 1 Credit™ (Expiration date: 3rd October 2023)
Completion of 15-minute patient case study 2: 0.25 AMA PRA Category 1 Credit™ (Expiration date: 19th October 2023)
How to claim your credits
To claim your credits for participating in the accredited activities, you will need to complete the activity then fill out the short evaluation form at the end of each module.
Planning Committee
In addition to the expert faculty, NACCME and Springer Healthcare IME planners and staff include Kristin Kolack, Rachel Goddard, James Hutton, and Rebecca Cox. The Planning Committee have no financial relationships to disclose.
All relevant financial relationships of the Faculty have been mitigated.
Sign up for new content alerts
Enter your email address below and we'll contact you as soon as new content is launched!
